ChemWerth, Inc. announces Wuhan Pharmaceutical Factory passes FDA inspection
ChemWerth Inc. reported the Wuhan Pharmaceutical Factory facility has passed an FDA overseas inspection with a two point 483 being issued. ChemWerth and Wuhan are collaborating to develop APIs for the U.S. and other regulated markets overseas. Wuhan continues to be a primary supplier of high quality active pharmaceutical ingredients to the Chinese and U.S. markets.
According to Mr. Peter Werth, CEO, “ChemWerth has been working with the FDA in China for over 25 years and has been through approximately 100 FDA inspections. Our regulatory expertise in helping manufactures like Wuhan get approved is a real value-added benefit for our customers. We’re proud to have Wuhan as a manufacturing partner.”
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.